Acute Leukemia and Myeloid Malignancies Rounds Philadelphia
Thursday, May 2, 2024
5:45 PM – 8.30 PM Eastern Time
Please enable JavaScript in your browser to complete this form.
1. 45-year-old male with anemia, fatigue, gum bleeding found to have Hb 6.7, platelets 30 K, WBC 10 K. Bone marrow biopsy showed B-cell, CD 20+, Ph positive (9:22) ALL. He has PS of 0 and has no known co morbidities. What is the most appropriate induction therapy for this patient?
a) Vincristine + Dexamethasone
b) Hyper-CVAD + Blinatumomab
c) Rituximab-Hyper-CVAD with alternating high dose Methotrexate and Ara-C + Ponatinib
d) Blinatumomab alone
2. Which JAK inhibitor also inhibits ACVR1?
a) Ruxolitinib
b) Fedratinib
c) Pacritinib
d) Momelotinib
e) Both C and D
3. What is the current ELN risk stratification for FLT3-ITD+ AML?
a. Favorable risk
b. Intermediate risk
c. Adverse risk
d. Depending on allelic ratio and NPM1 status
Submit
Claim credit
Scroll to Top
